Veradigm (MDRX) Competitors $4.05 -0.21 (-4.82%) As of 03/27/2025 03:23 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSustainabilityTrendsBuy This Stock MDRX vs. OMCL, HSTM, CRTX, AGYS, NTCT, VRNT, ECX, RBBN, OSPN, and SLPShould you be buying Veradigm stock or one of its competitors? The main competitors of Veradigm include Omnicell (OMCL), HealthStream (HSTM), Cortexyme (CRTX), Agilysys (AGYS), NetScout Systems (NTCT), Verint Systems (VRNT), ECARX (ECX), Ribbon Communications (RBBN), OneSpan (OSPN), and Simulations Plus (SLP). Veradigm vs. Omnicell HealthStream Cortexyme Agilysys NetScout Systems Verint Systems ECARX Ribbon Communications OneSpan Simulations Plus Omnicell (NASDAQ:OMCL) and Veradigm (NASDAQ:MDRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations, community ranking and profitability. Does the MarketBeat Community prefer OMCL or MDRX? Veradigm received 128 more outperform votes than Omnicell when rated by MarketBeat users. However, 66.80% of users gave Omnicell an outperform vote while only 57.97% of users gave Veradigm an outperform vote. CompanyUnderperformOutperformOmnicellOutperform Votes50166.80% Underperform Votes24933.20% VeradigmOutperform Votes62957.97% Underperform Votes45642.03% Do analysts recommend OMCL or MDRX? Omnicell currently has a consensus target price of $51.00, suggesting a potential upside of 44.27%. Veradigm has a consensus target price of $14.00, suggesting a potential upside of 245.68%. Given Veradigm's stronger consensus rating and higher probable upside, analysts clearly believe Veradigm is more favorable than Omnicell.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omnicell 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Veradigm 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is OMCL or MDRX more profitable? Omnicell has a net margin of 1.13% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 3.82% beat Veradigm's return on equity.Company Net Margins Return on Equity Return on Assets Omnicell1.13% 3.82% 2.07% Veradigm N/A N/A N/A Does the media refer more to OMCL or MDRX? In the previous week, Omnicell had 8 more articles in the media than Veradigm. MarketBeat recorded 11 mentions for Omnicell and 3 mentions for Veradigm. Omnicell's average media sentiment score of 0.56 beat Veradigm's score of 0.51 indicating that Omnicell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Veradigm 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, OMCL or MDRX? Omnicell has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Veradigm has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Which has stronger valuation & earnings, OMCL or MDRX? Omnicell has higher earnings, but lower revenue than Veradigm. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOmnicell$1.11B1.49$12.53M$0.27130.93Veradigm$1.53B0.29N/AN/AN/A Do institutionals & insiders hold more shares of OMCL or MDRX? 97.7% of Omnicell shares are held by institutional investors. 2.6% of Omnicell shares are held by company insiders. Comparatively, 2.3% of Veradigm shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryOmnicell beats Veradigm on 11 of the 15 factors compared between the two stocks. Remove Ads Get Veradigm News Delivered to You Automatically Sign up to receive the latest news and ratings for MDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDRX vs. The Competition Export to ExcelMetricVeradigmComputer integrated systems design IndustryBusiness SectorNASDAQ ExchangeMarket Cap$435.94M$3.57B$7.25B$8.06BDividend YieldN/A2.22%2.53%4.02%P/E RatioN/A60.3630.2919.03Price / Sales0.2926.05158.1593.17Price / CashN/A34.8531.5134.64Price / BookN/A4.964.884.33Net IncomeN/A$38.20M$195.43M$247.06M7 Day Performance-8.58%-2.20%0.39%-0.52%1 Month Performance-19.00%-6.13%-2.82%-3.73%1 Year Performance-48.08%-10.22%6.12%1.74% Veradigm Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDRXVeradigm2.7971 of 5 stars$4.05-4.8%$14.00+245.7%-48.1%$435.94M$1.53B0.008,000Analyst ForecastGap DownOMCLOmnicell3.1138 of 5 stars$33.22+0.7%$52.33+57.5%+20.9%$1.55B$1.11B123.043,650HSTMHealthStream3.7102 of 5 stars$31.04-0.1%$32.00+3.1%+23.6%$944.67M$291.65M47.751,140News CoveragePositive NewsCRTXCortexymeN/A$1.44+2.1%N/A+18.6%$43.42MN/A-0.4855AGYSAgilysys3.5548 of 5 stars$74.91+0.8%$127.50+70.2%-8.3%$2.09B$263.57M93.641,400Analyst RevisionPositive NewsNTCTNetScout Systems1.7256 of 5 stars$21.05+1.5%$25.00+18.8%-0.3%$1.51B$821.14M-3.592,296VRNTVerint Systems4.3301 of 5 stars$22.56+3.7%$35.67+58.1%-39.8%$1.41B$920.75M24.003,700Earnings ReportAnalyst ForecastNews CoverageGap DownECXECARX2.3873 of 5 stars$2.64-2.6%$3.20+21.2%+15.9%$892.19M$5.56B-5.282,020Short Interest ↑Gap UpHigh Trading VolumeRBBNRibbon Communications4.3012 of 5 stars$3.95flat$6.00+51.9%+22.6%$694.11M$833.88M-12.343,107OSPNOneSpan4.7761 of 5 stars$16.11+2.3%$17.63+9.4%+35.8%$615.02M$243.18M21.77790Analyst DowngradeSLPSimulations Plus4.0418 of 5 stars$26.23+0.6%$49.40+88.3%-41.5%$527.01M$74.44M65.58160Upcoming Earnings Remove Ads Related Companies and Tools Related Companies Omnicell Competitors HealthStream Competitors Cortexyme Competitors Agilysys Competitors NetScout Systems Competitors Verint Systems Competitors ECARX Competitors Ribbon Communications Competitors OneSpan Competitors Simulations Plus Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDRX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veradigm Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veradigm With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
